Pangaea Oncology - Public Comps and Valuation Multiples

Pangaea Oncology Overview

About Pangaea Oncology

Pangaea Oncology SA is a medical services company. The company provides a wide range of services to cancer patients, as well as global pharmaceutical and biotech clients, in the fields of molecular diagnostics, clinical trials, in vitro drug profiling, dx platform validation, and biomarker discovery. The company has aggregated its operations into two segments, Clinical Care division and Diagnostic and Research and Development services division. Clinical Care division delivers medical oncology services and related activities. Diagnostic and Research and Development services division provides diagnostic and in-vitro services.

Founded

2007

HQ

Employees

Website

panoncology.com

Sectors

Medical Imaging & Diagnostics
HealthTech

Financials

LTM Revenue $19.0M

LTM EBITDA -$2.9M

EV

$70.4M

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Pangaea Oncology Financials

As of December 2025, Pangaea Oncology reported last 12-month revenue of $19.0M and EBITDA of -$2.9M.

In the same period, Pangaea Oncology generated $14.7M in LTM gross profit and -$2.8M in net income.

See Pangaea Oncology valuation multiples based on analyst estimates

Pangaea Oncology P&L

In the most recent fiscal year, Pangaea Oncology reported revenue of $16.6M and EBITDA of $1.4M.

Pangaea Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Pangaea Oncology valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue	$19.0M	XXX	$16.6M	XXX	XXX	XXX
Gross Profit	$14.7M	XXX	$16.6M	XXX	XXX	XXX
Gross Margin	77%	XXX	100%	XXX	XXX	XXX
EBITDA	-$2.9M	XXX	$1.4M	XXX	XXX	XXX
EBITDA Margin	-15%	XXX	8%	XXX	XXX	XXX
EBIT	-$2.9M	XXX	-$2.3M	XXX	XXX	XXX
EBIT Margin	-15%	XXX	-14%	XXX	XXX	XXX
Net Profit	-$2.8M	XXX	-$1.4M	XXX	XXX	XXX
Net Margin	-15%	XXX	-8%	XXX	XXX	XXX
Net Debt	XXX	XXX	$2.6M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Pangaea Oncology including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $19.0M. EBITDA for the last twelve months was -$2.9M. In the most recent fiscal year, Pangaea Oncology achieved $16.6M in revenue and $1.4M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2026)	Next Fiscal Year (2027)	Two Years Forward (2028)
Total Revenue	$19.0M	Analyst estimates available to subscribers	$16.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$14.7M	Analyst estimates available to subscribers	$16.6M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	77.4% gross margin	Analyst estimates available to subscribers	100.1% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	-$2.9M	Analyst estimates available to subscribers	$1.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	-15.2% EBITDA margin	Analyst estimates available to subscribers	8.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	-$2.9M	Analyst estimates available to subscribers	-$2.3M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	-15.2% EBIT margin	Analyst estimates available to subscribers	-14.0% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	-$2.8M	Analyst estimates available to subscribers	-$1.4M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	-14.6% net profit margin	Analyst estimates available to subscribers	-8.2% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$2.6M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Pangaea Oncology

This financial data table provides comprehensive performance metrics for Pangaea Oncology, a company based in Spain. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Pangaea Oncology generated $19.0M in revenue over the last twelve months.
The company achieved -$2.9M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $14.7M.
Net income over the last twelve months reached -$2.8M.

Fiscal Year Performance

In the most recent fiscal year, Pangaea Oncology reported $16.6M in total revenue.
Fiscal year EBITDA was $1.4M.
The company maintained a gross profit margin of 100.1% in the most recent fiscal year.
EBITDA margin for the fiscal year was 8.3%.
Net profit margin reached -8.2% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Pangaea Oncology. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Pangaea Oncology Stock Performance

Pangaea Oncology has current market cap of EUR 57.7M (or $66.9M), and EV of EUR 60.6M (or $70.4M).

Market Cap Evolution

Pangaea Oncology Stock Data

As of January 19, 2026, Pangaea Oncology's stock price is EUR 2 (or $2).

See Pangaea Oncology trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$70.4M	$66.9M	XXX	XXX	XXX	XXX	$-0.09

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Pangaea Oncology Valuation Multiples

Pangaea Oncology's trades at 3.7x EV/Revenue multiple, and -24.3x EV/EBITDA.

See valuation multiples for Pangaea Oncology and 15K+ public comps

Pangaea Oncology Financial Valuation Multiples

As of January 19, 2026, Pangaea Oncology has market cap of $66.9M and EV of $70.4M.

Equity research analysts estimate Pangaea Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Pangaea Oncology has a P/E ratio of -24.0x.

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Market cap (current)	$66.9M	XXX	$66.9M	XXX	XXX	XXX
EV (current)	$70.4M	XXX	$70.4M	XXX	XXX	XXX
EV/Revenue	3.7x	XXX	3.7x	XXX	XXX	XXX
EV/EBITDA	-24.3x	XXX	-24.3x	XXX	XXX	XXX
EV/EBIT	-24.3x	XXX	-24.3x	XXX	XXX	XXX
EV/Gross Profit	4.8x	XXX	n/a	XXX	XXX	XXX
P/E	-24.0x	XXX	-24.0x	XXX	XXX	XXX
EV/FCF	-86.6x	XXX	-86.6x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Pangaea Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Pangaea Oncology Margins & Growth Rates

Pangaea Oncology's last 12 month revenue growth is 12%

Pangaea Oncology's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

Pangaea Oncology's rule of 40 is -7% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Pangaea Oncology's rule of X is 15% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Pangaea Oncology and other 15K+ public comps

Pangaea Oncology Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2026	FY 2027	FY 2028
Revenue Growth	12%	XXX	12%	XXX	XXX	XXX
EBITDA Margin	-15%	XXX	-15%	XXX	XXX	XXX
EBITDA Growth	-72%	XXX	n/a	XXX	XXX	XXX
Rule of 40	-7%	XXX	-3%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	15%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.3M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	1%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	114%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial